- Home
- AVXL vs CVAC Comparison
AVXL vs CVAC Comparison
Compare AVXL & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- CVAC
- Stock Information
- Founded
- AVXL 2004
- CVAC 2000
- Country
- AVXL United States
- CVAC Germany
- Employees
- AVXL N/A
- CVAC N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- AVXL Health Care
- CVAC Health Care
- Exchange
- AVXL Nasdaq
- CVAC Nasdaq
- Market Cap
- AVXL 876.0M
- CVAC 812.1M
- IPO Year
- AVXL N/A
- CVAC 2020
- Fundamental
- Price
- AVXL $9.21
- CVAC $4.10
- Analyst Decision
- AVXL Strong Buy
- CVAC Hold
- Analyst Count
- AVXL 2
- CVAC 3
- Target Price
- AVXL $44.00
- CVAC $10.00
- AVG Volume (30 Days)
- AVXL 2.9M
- CVAC 1.2M
- Earning Date
- AVXL 02-05-2025
- CVAC 11-12-2024
- Dividend Yield
- AVXL N/A
- CVAC N/A
- EPS Growth
- AVXL N/A
- CVAC N/A
- EPS
- AVXL N/A
- CVAC N/A
- Revenue
- AVXL N/A
- CVAC $70,565,734.00
- Revenue This Year
- AVXL N/A
- CVAC $742.57
- Revenue Next Year
- AVXL N/A
- CVAC N/A
- P/E Ratio
- AVXL N/A
- CVAC N/A
- Revenue Growth
- AVXL N/A
- CVAC 75.11
- 52 Week Low
- AVXL $3.25
- CVAC $2.22
- 52 Week High
- AVXL $14.44
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- AVXL 43.28
- CVAC 62.06
- Support Level
- AVXL $10.04
- CVAC $3.89
- Resistance Level
- AVXL $11.68
- CVAC $4.32
- Average True Range (ATR)
- AVXL 1.22
- CVAC 0.33
- MACD
- AVXL -0.35
- CVAC 0.03
- Stochastic Oscillator
- AVXL 4.52
- CVAC 54.27
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.